Viatris Inc (VTRS)
9.33
0.00 (0.00%)
USD |
NASDAQ |
Jun 05, 16:00
9.33
0.00 (0.00%)
After-Hours: 17:26
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.19B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -19.27% |
| Valuation | |
| PE Ratio | 5.943 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7178 |
| Price to Book Value | 0.5345 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.12 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8971 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 82.15% |
Profile
| Viatris Inc is one of the world’s largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company’s branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone). |
| URL | https://www.viatris.com |
| Investor Relations URL | https://investor.viatris.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Aug. 08, 2023 (est.) |
| Last Earnings Release | May. 08, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 23, 2023 |
Ratings
Profile
| Viatris Inc is one of the world’s largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company’s branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone). |
| URL | https://www.viatris.com |
| Investor Relations URL | https://investor.viatris.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Aug. 08, 2023 (est.) |
| Last Earnings Release | May. 08, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 23, 2023 |